Watch FBLG. Know when insiders buy.
One email the day a filing lands. Free.
FBLG
FibroBiologics, Inc.
1.61
−0.12 −6.94%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
3
FLAG · shorts 3
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.7MP/E —DIV YIELD —FCF YIELD -138.03%REV TTM —NET INCOME −$18.1MNET CASH —52W 0.63 – 12.24SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4M | −$4.1M | — | -0.66 | −$3.3M | $0 | −$3.3M | Jul 31 |
| Q1 2026 · Mar 31 | — | — | — | −$5.1M | −$5M | — | -1.33 | −$4.4M | $0 | −$4.4M | Jul 31 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.6M | −$3.2M | — | -0.03 | −$3.2M | $0 | −$3.2M | Feb 24 |
| Q3 2025 · Sep 30 | — | — | — | −$5M | −$5.8M | — | -0.13 | −$4M | $6K | −$4M | Oct 31 |
| Q2 2025 · Jun 30 | — | — | — | −$4.5M | −$4.7M | −618.7% | -2.41 | −$4M | $213K | −$4.2M | Jul 31 |
| Q1 2025 · Mar 31 | — | — | — | −$4.5M | −$5M | — | -2.71 | −$5.3M | $43K | −$5.3M | Jul 31 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.7M | −$3.1M | — | -0.09 | −$3.1M | $99K | −$3.2M | Feb 24 |
| Q3 2024 · Sep 30 | — | — | — | −$3.4M | −$500K | — | -0.01 | −$2.6M | $11K | −$2.6M | Oct 31 |
| Q2 2024 · Jun 30 | — | — | — | −$3.2M | $898K | — | 0.03 | −$1.9M | $66K | −$2M | Oct 31 |
| Q1 2024 · Mar 31 | — | — | — | −$3.5M | −$8.5M | — | -0.27 | −$4.3M | $8K | −$4.3M | Oct 31 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.5M | −$9.7M | — | -0.35 | −$1.6M | $2K | −$1.6M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$2.1M | −$2.2M | — | -0.08 | −$1.1M | $413K | −$1.6M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$16.6M | −$18.6M | — | -0.42 | −$16.4M | $262K | −$16.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$13.7M | −$11.2M | — | -0.34 | −$11.9M | $184K | −$12.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$8.9M | −$16.5M | — | -0.68 | −$6.4M | $495K | −$6.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$4.5M | −$5.1M | — | -0.18 | −$4.1M | — | — | — | — |
Every number comes from FibroBiologics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.